- Conditions
- Basal Cell Carcinoma
- Interventions
- Vismodegib
- Drug
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 52
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Basal Cell Carcinoma
- Interventions
- vismodegib (GDC-0449)
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 11
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Stanford, California + 7 more
- Conditions
- Pontine Glioma
- Interventions
- Vismodegib
- Drug
- Lead sponsor
- Giselle Sholler
- Other
- Eligibility
- 3 Years to 18 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Grand Rapids, Michigan
- Conditions
- Basal Cell Carcinoma of the Skin, Recurrent Skin Cancer
- Interventions
- vismodegib, Mohs surgery
- Drug · Procedure
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7
- Interventions
- Gemcitabine Hydrochloride, Hydrocortisone/Placebo, Vismodegib
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 21 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 25
- States / cities
- Beverly Hills, California • Duarte, California • Los Angeles, California + 19 more
- Conditions
- Recurrent Childhood Medulloblastoma
- Interventions
- Laboratory Biomarker Analysis, Pharmacological Study, Vismodegib
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 9 more
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma
- Interventions
- Adavosertib, Afatinib, Afatinib Dimaleate, Binimetinib, Biopsy Procedure, Biospecimen Collection, Capivasertib, Computed Tomography, Copanlisib, Copanlisib Hydrochloride, Crizotinib, Cytology Specimen Collection Procedure, Dabrafenib, Dabrafenib Mesylate, Dasatinib, Defactinib, Defactinib Hydrochloride, Echocardiography Test, Erdafitinib, Fexagratinib, Ipatasertib, Laboratory Biomarker Analysis, Larotrectinib, Larotrectinib Sulfate, Magnetic Resonance Imaging, Multigated Acquisition Scan, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-beta Inhibitor GSK2636771, Radiologic Examination, Radionuclide Imaging, Relatlimab, Sapanisertib, Sunitinib Malate, Taselisib, Trametinib, Trastuzumab, Trastuzumab Emtansine, Ulixertinib, Vismodegib
- Drug · Procedure · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 6,452 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 1405
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 847 more
- Conditions
- Basal Cell Carcinoma
- Interventions
- SP-002, Vismodegib
- Drug
- Lead sponsor
- Stamford Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Boca Raton, Florida • Coral Springs, Florida + 7 more
- Conditions
- Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
- Interventions
- Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacogenomic Study, Pharmacological Study, Vismodegib
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Ann Arbor, Michigan • Detroit, Michigan
- Conditions
- Locally Advanced Basal Cell Carcinoma, Skin Cancer, Cutaneous Malignancy
- Interventions
- Vismodegib, Radiation therapy
- Drug · Radiation
- Lead sponsor
- Sue Yom
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 2
- States / cities
- San Francisco, California • New York, New York
- Conditions
- Basal Cell Nevus Syndrome, Gorlin's Syndrome
- Interventions
- Vismodegib, Aminolevulinic acid %20 topical solution
- Drug
- Lead sponsor
- UCSF Benioff Children's Hospital Oakland
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 3
- States / cities
- Oakland, California • New York, New York
- Conditions
- DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Interventions
- Vismodegib, Pharmacological Study, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland
- Conditions
- Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, PARP Inhibitor, Hedgehog Inhibitor
- Interventions
- Vismodegib, Atezolizumab
- Drug
- Lead sponsor
- Ronald Buckanovich
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Myelofibrosis
- Interventions
- Placebo, Ruxolitinib, Vismodegib
- Other · Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 6
- States / cities
- Fort Myers, Florida • St. Petersburg, Florida • West Palm Beach, Florida + 3 more
- Conditions
- Cancer
- Interventions
- Vismodegib
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Baltimore, Maryland • Detroit, Michigan + 2 more
- Conditions
- Extensive Stage Small Cell Lung Carcinoma, Recurrent Small Cell Lung Carcinoma
- Interventions
- Cisplatin, Cixutumumab, Etoposide, Laboratory Biomarker Analysis, Vismodegib
- Drug · Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 301
- States / cities
- Scottsdale, Arizona • Palo Alto, California • Aurora, Colorado + 205 more
- Conditions
- Ovarian Cancer, Basal Cell Carcinoma, Metastatic Colorectal Cancer
- Interventions
- Vismodegib, FOLFOX, FOLFIRI, Bevacizumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • Oakland, California • Palm Springs, California + 7 more
- Conditions
- Basal Cell Carcinoma
- Interventions
- Vismodegib, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 17
- States / cities
- Los Angeles, California • Palo Alto, California • San Diego, California + 13 more
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage IIIA Gastric Cancer, Stage IIIB Gastric Cancer, Stage IIIC Gastric Cancer, Stage IV Gastric Cancer
- Interventions
- oxaliplatin, leucovorin calcium, fluorouracil, placebo, vismodegib, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 30
- States / cities
- Sacramento, California • Chicago, Illinois • Decatur, Illinois + 16 more
- Conditions
- Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
- Interventions
- Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, Abemaciclib
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2028
- U.S. locations
- 783
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 511 more
- Conditions
- Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Hemangioendothelioma, Adult Epithelioid Sarcoma, Adult Extraskeletal Myxoid Chondrosarcoma, Adult Extraskeletal Osteosarcoma, Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Mesenchymoma, Adult Malignant Peripheral Nerve Sheath Tumor, Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Adult Unclassified Pleomorphic Sarcoma, Chondrosarcoma, Clear Cell Sarcoma of the Kidney, Conjunctival Kaposi Sarcoma, Dermatofibrosarcoma Protuberans, Gastrointestinal Stromal Tumor, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Osteosarcoma, Ovarian Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Adult Unclassified Pleomorphic Sarcoma of Bone, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Kaposi Sarcoma, Recurrent Osteosarcoma, Recurrent Uterine Corpus Sarcoma, Small Intestine Leiomyosarcoma, Stage III Adult Soft Tissue Sarcoma, Stage III Uterine Sarcoma, Stage IV Adult Soft Tissue Sarcoma, Stage IV Uterine Sarcoma, Unclassified Pleomorphic Sarcoma of Bone
- Interventions
- Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study, Vismodegib
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Myelodysplastic Syndromes, Myelogenous Leukemia, Acute
- Interventions
- cytarabine, vismodegib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 5
- States / cities
- Stanford, California • Ann Arbor, Michigan • Kansas City, Missouri + 2 more
- Conditions
- Basal Cell Nevus Syndrome, Gorlin Syndrome
- Interventions
- GDC-0449
- Drug
- Lead sponsor
- UCSF Benioff Children's Hospital Oakland
- Other
- Eligibility
- 35 Years to 75 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 2
- States / cities
- Oakland, California • New York, New York
- Conditions
- Recurrent Childhood Medulloblastoma
- Interventions
- vismodegib, laboratory biomarker analysis, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 9
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 5 more